MarketPulse
E

$ESPR

2 articles found
1 positive
1 negative
0 neutral
BenzingaBenzinga··Nabaparna Bhattacharya

Esperion Acquires Enbumyst Maker Corstasis for $75M in Cash-Plus-Milestone Deal

Esperion acquires Corstasis for $75M upfront plus $180M in milestones, gaining FDA-approved nasal spray diuretic Enbumyst for heart failure treatment.
ESPRacquisitionFDA-approved
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Esperion Secures Fifth Settlement with Generic Drug Maker Over NEXLETOL, NEXLIZET Patents

Esperion secures fifth settlement with generic drugmaker Alkem, extending market exclusivity for cholesterol drugs NEXLETOL and NEXLIZET through April 2040.
SDZNYESPRpatent settlementgeneric drugs